s
s
s
Develop highly selective and sensitive PK and ADA assays for pertuzumab (Perjeta) using our range of ready-made antibodies.
Table 1. Antibodies Specific to Pertuzumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Pertuzumab Inhibitory Type 1
|
HCA341 |
AbD35668 |
Fab-FSx21 |
14 |
PK bridging ELISA |
|
HCA342 |
AbD37070 |
Fab-FH2 |
0.7 |
PK bridging ELISA |
||
HCA344 |
AbD35668ia |
Human IgG1 |
14 |
ADA control |
||
HCA345 |
AbD37069ia |
Human IgG1 |
2 |
PK bridging ELISA ADA control |
* Affinity measured in the monovalent Fab format.
1 Monovalent Fab antibody with (F) DYKDDDDK, and (Sx2) StrepX-StrepX tags.
2 Monovalent Fab antibody with (F) DYKDDDDK, and (H) His-6 tags.
Type 1 anti-pertuzumab antibodies inhibit the binding of the monoclonal antibody drug pertuzumab to its target, human epidermal growth factor receptor 2 (HER2). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. They are available in fully human IgG1 format, in two different affinities, for use as a surrogate positive control or reference standard for an anti-drug antibody (ADA) assay.
Fig. 1. Pertuzumab PK bridging ELISA using antibodies HCA342 and HCA345.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
Fig. 2. Pertuzumab ADA bridging ELISA using antibody HCA344 or HCA345.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.